AB Science announces a slight delay in the publication of its 2024 half-year financial report
30/09/2024 – The Company will publish its financial report for the first half of 2024 on Monday 7 October 2024
AB Science announces the success of a 5.0 million euros capital increase
30/09/2024 – AB Science announces today the success of a capital increase by private placement for an amount of 5 million euros
AB Science provides an update on the microtubule program AB8939
26/09/2024 – AB Science today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
23/09/2024 – AB Science today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference